MayoComplete Solid Tumor Panel
Test in Focus
The MayoComplete Solid Tumor Panel — Mayo Clinic Laboratories’ most comprehensive genetic profiling assay to date — uses next-generation sequencing to check for mutations in 514 cancer-related genes known to have clinical significance. In this “Test in Focus” episode of the "Answers From the Lab" podcast, co-director of Mayo Clinic’s Genomics Laboratory, Kevin Halling, M.D., Ph.D., discusses how the comprehensive panel provides wide-ranging yet highly detailed information on genetic alterations.
“It’s almost like five tests in one,” Dr. Halling says. “What we typically observe is about five to 10 clinically significant alterations per case, but sometimes many more mutations if it’s a highly mutated tumor.”
The comprehensive panel tests genes across a spectrum of cancer types, providing insights that not only establish diagnosis and predicts prognosis, but guide therapeutic decisions.
“It may be used for any patient with an advanced, solid tumor as a way of identifying which patients may benefit from either immunotherapy or specific targeted therapies,” Dr. Halling says.
Listen to learn more about how the MayoComplete Solid Tumor panel advances genetic testing to optimize treatment choices for solid tumor patients.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
MCSTP | MayoComplete Solid Tumor Panel
This assay requires at least 20% tumor nuclei. However, 40% tumor is preferred.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.